moneyheap
VTRS · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Viatris Inc. Common Stock (VTRS) stock moving?
VTRS has risen from $18.00 on Oct 23 to $20.85 on Nov 10, about 16%, and closed at its session high on Nov 10. The move accelerated after Q3 results on Nov 5: the stock closed at $18.97 that day and gained about 10% over the next three sessions, on volume of 11.9M, 14.5M and 12.6M shares versus a typical 6-8M in late October. Q3 adjusted EPS of $0.71 beat the $0.64 estimate, and FY2026 adjusted EPS guidance was raised to $2.56-$2.63 from $2.45-$2.49, above the $2.51 estimate. Sales of $3.749B missed the $3.786B estimate, and the GAAP net loss of $325.3M (-$0.28 per share) is a weak point, though the sales guidance was narrowed to a range that brackets consensus. Analysts followed with higher targets: UBS raised its target to $28 from $26 with a Buy rating, and Jefferies raised its target to $22 from $20. The pending $1.65B cash acquisition of Pacira BioSciences at $36.50 per share, expected to close by year-end 2026, adds integration and financing risk but is described by management as accretive to guidance metrics. Other supportive items include a surge in estradiol product demand and a $0.12 quarterly dividend. The stock's VWAP of $20.67 sits just below the last close, which suggests buying into the close, while the Nov 4 close near $19.22 and the Oct 29 high near $19.23 mark the nearest prior area the price has moved through.
News behind the analysis
- Viatris Q3 2026 Earnings Call TranscriptViatris reported Q3 2026 results on Nov 5 and held its earnings call with management commentary on the quarter and outlook.
- Viatris Raises FY2026 Adj EPS Guidance from $2.45-$2.49 to $2.56-$2.63 vs $2.51 Est; Narrows FY2026 Sales Guidance from $14.550B-$14.950B to $14.700B-$14.900B vs $14.788B EstViatris raised its FY2026 adjusted EPS guidance to $2.56-$2.63, above the $2.51 estimate, and narrowed its sales guidance to $14.700B-$14.900B, in line with the $14.788B estimate.
- Viatris Q3 Adj. EPS $0.71 Beats $0.64 Estimate, Sales $3.749B Miss $3.786B EstimateAdjusted EPS of $0.71 beat the $0.64 estimate, while sales of $3.749B missed the $3.786B estimate. The company also reported a GAAP net loss of $325.3M, or -$0.28 per share.
- Viatris Reports Q3 2026 Financial Results and Raises 2026 GuidanceViatris reported Q3 2026 results with a net loss of $325.3M and EPS of -$0.28, while raising full-year 2026 guidance across key metrics.
- UBS Adjusts Viatris Price Target to $28 From $26, Maintains Buy RatingUBS raised its price target on Viatris to $28 from $26 and kept its Buy rating.
- Jefferies Adjusts Viatris Price TargetJefferies raised its price target on Viatris to $22 from $20.
- Viatris Begins $36.50 Per Share Cash Tender Offer for Pacira BioSciencesViatris has commenced a cash tender offer to acquire all outstanding Pacira BioSciences shares at $36.50 per share, an aggregate equity value of $1.65B. The deal is expected to close by the end of 2026.
- Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/ShrViatris subsidiary Peach Purchaser Sub has started the tender offer for Pacira Biosciences at $36.50 per share.
- Viatris Addresses Supply Demand for Estradiol ProductsViatris reported a significant surge in demand for its estradiol patches and creams and described steps to expand production capacity.
- Viatris Declares Quarterly DividendViatris declared a quarterly cash dividend of $0.12 per share.
About Viatris Inc. Common Stock
Viatris is a global drug company based near Pittsburgh. It was formed in 2020 when Mylan merged with Pfizer's Upjohn unit. It sells a large portfolio of generic, branded and off-patent drugs (such as Lipitor, Norvasc and Viagra) in many countries, and is now adding newer specialty products, including a planned acquisition of Pacira BioSciences.
How it makes money
Almost all of its revenue comes from drug sales, about $15 billion a year in total (approximately $14.7–14.9 billion expected for 2026). Sales are a mix of off-patent brands, generics (about $1.3 billion a quarter) and complex injectables. It reports results by region: Developed Markets (the largest, covering North America and Europe), Greater China, JANZ (Japan, Australia and New Zealand) and Emerging Markets. Its top ten products make up roughly 40% of net sales. It also pays a regular dividend of $0.48 per share a year.
What usually moves VTRS
- Price erosion and competition in generics
- New product launches and pipeline approvals
- Acquisitions such as the Pacira BioSciences deal
- Debt reduction, cost cuts and restructuring
- Currency swings and sales trends in China and emerging markets